TUCSON, Ariz. , March 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter and year ended December 31, 2017 after
Patent covers methods of co-detecting mRNA and small non-coding RNA TUCSON, Ariz. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the issuance of Australian
TUCSON, Ariz. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that management will present in a fireside chat at the LEERINK Partners 7th Annual Global
TUCSON, Ariz. , Jan. 23, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the completion of its previously announced underwritten public offering of 13,915,000 shares
TUCSON, Ariz. , Jan. 18, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the pricing of an underwritten public offering of 12,100,000 shares of its common stock at a
TUCSON, Ariz. , Jan. 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that it intends to offer and sell, subject to market and other conditions, 10,000,000 shares
TUCSON, Ariz. , Jan. 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced it has entered into a third statement of work for a new clinical assay development program
Fourth quarter 2017 revenue expected to be between $6.9 and $7.2 million Full year 2017 revenue expected to be between $13.8 and $14.1 million Initial full year 2018 revenue guidance of $20.0 to $25.0 million TUCSON, Ariz. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
Signs Master Collaboration Agreement for Assay Development and Manufacturing of Kits Supporting Biomarker Research Programs TUCSON, Ariz. and DARMSTADT, Germany , Dec. 26, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for
TUCSON, Ariz. , Dec. 20, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (NASDAQ:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that its senior management team will host institutional investor and partnering meetings at the
